We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Two leading House lawmakers are investigating FDA Commissioner Andrew von Eschenbach’s recent testimony on Ketek over concerns that he may have “intentionally misled” a subcommittee about the drug’s approval process.
After pressure from Congress, federal investigators will reopen 103 cases of potential conflicts of interest among NIH employees, according to HHS Inspector General Daniel Levinson.
The HHS Secretary’s Advisory Committee on Human Research Protections (SACHRP) has a new chairman, Samuel Tilden, following the resignation last November of Ernest Prentice.
Antidepressants are no more effective than placebo for depressed people with bipolar disorder who are taking a mood stabilizer, according to a study in the New England Journal of Medicine.
HHS Secretary Mike Leavitt is calling for a new healthcare system in the U.S. modeled after the Medicare Part D drug benefit and based on competition and quality standards.
HHS Secretary Michael Leavitt is calling for a new healthcare system in the U.S. modeled after the Medicare Part D drug benefit and based on competition and quality standards.
HHS Secretary Michael Leavitt is calling for a new healthcare system in the U.S. modeled after the Medicare Part D drug benefit and based on competition and quality standards.
An analysis of 84 studies by HHS’ Agency for Healthcare Research and Quality (AHRQ) found no strong evidence that atypical antipsychotics are effective for many of the off-label uses for which they are commonly prescribed.